ES3050608T3 - Improved reprogramming methods and cell culture platforms - Google Patents

Improved reprogramming methods and cell culture platforms

Info

Publication number
ES3050608T3
ES3050608T3 ES20207188T ES20207188T ES3050608T3 ES 3050608 T3 ES3050608 T3 ES 3050608T3 ES 20207188 T ES20207188 T ES 20207188T ES 20207188 T ES20207188 T ES 20207188T ES 3050608 T3 ES3050608 T3 ES 3050608T3
Authority
ES
Spain
Prior art keywords
cell culture
reprogramming methods
culture platforms
improved reprogramming
improved
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES20207188T
Other languages
English (en)
Spanish (es)
Inventor
Bahram Valamehr
Peter Flynn
Ramzey Abujarour
Megan Robinson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fate Therapeutics Inc
Original Assignee
Fate Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fate Therapeutics Inc filed Critical Fate Therapeutics Inc
Application granted granted Critical
Publication of ES3050608T3 publication Critical patent/ES3050608T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/15—Transforming growth factor beta (TGF-β)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/235—Leukemia inhibitory factor [LIF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/415—Wnt; Frizzeled
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/603—Oct-3/4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/72—Transferases [EC 2.]
    • C12N2501/724—Glycosyltransferases (EC 2.4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/72—Transferases [EC 2.]
    • C12N2501/727—Kinases (EC 2.7.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Transplantation (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
ES20207188T 2014-03-04 2015-03-04 Improved reprogramming methods and cell culture platforms Active ES3050608T3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461947979P 2014-03-04 2014-03-04

Publications (1)

Publication Number Publication Date
ES3050608T3 true ES3050608T3 (en) 2025-12-22

Family

ID=54055848

Family Applications (2)

Application Number Title Priority Date Filing Date
ES20207188T Active ES3050608T3 (en) 2014-03-04 2015-03-04 Improved reprogramming methods and cell culture platforms
ES15757753T Active ES2966757T3 (es) 2014-03-04 2015-03-04 Métodos de reprogramación mejorados y plataformas de cultivo celular

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES15757753T Active ES2966757T3 (es) 2014-03-04 2015-03-04 Métodos de reprogramación mejorados y plataformas de cultivo celular

Country Status (11)

Country Link
US (2) US11268069B2 (enExample)
EP (4) EP4647498A2 (enExample)
JP (7) JP6722108B2 (enExample)
KR (4) KR102670874B1 (enExample)
CN (3) CN120536340A (enExample)
AU (3) AU2015227184B2 (enExample)
CA (1) CA2941004A1 (enExample)
ES (2) ES3050608T3 (enExample)
PT (1) PT3114214T (enExample)
SG (2) SG10201807292YA (enExample)
WO (1) WO2015134652A1 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101975688B1 (ko) 2010-12-22 2019-05-07 페이트 세러퓨틱스, 인코포레이티드 단세포 분류 및 iPSC의 증강된 재프로그래밍을 위한 세포 배양 플랫폼
KR102670874B1 (ko) 2014-03-04 2024-05-31 페이트 세러퓨틱스, 인코포레이티드 개선된 재프로그래밍 방법 및 세포 배양 플랫폼
US10023879B2 (en) * 2014-06-04 2018-07-17 Fate Therapeutics, Inc. Minimal volume reprogramming of mononuclear cells
JP6800859B2 (ja) 2015-01-26 2020-12-16 フェイト セラピューティクス，インコーポレイテッド 造血細胞分化を誘導するための方法および組成物
JP2018520688A (ja) 2015-07-21 2018-08-02 ザ チルドレンズ メディカル センター コーポレーション Ｐｄ−ｌ１発現造血幹細胞およびその使用
EP3362570A4 (en) * 2015-10-16 2019-03-20 Fate Therapeutics, Inc. PLATFORM FOR THE INDUCTION AND MAINTENANCE OF BASIC STATUS PLURIPOTENCE
HK1256552A1 (zh) 2015-10-21 2019-09-27 印第安纳大学研究与技术公司 生成人内耳感觉上皮和感觉神经元的方法
EP3371314B1 (en) 2015-11-04 2023-07-05 Fate Therapeutics, Inc. Genomic engineering of pluripotent cells
KR20250033315A (ko) 2015-11-04 2025-03-07 페이트 세러퓨틱스, 인코포레이티드 조혈 세포 분화를 유도하기 위한 방법 및 조성물
CA3010764A1 (en) * 2016-01-12 2017-07-20 Lonza Walkersville, Inc. Methods and vectors to produce vector free induced pluripotent stem cells
KR102537361B1 (ko) * 2016-12-27 2023-05-26 스미또모 가가꾸 가부시키가이샤 인공 다능성 줄기 세포의 평가 방법 및 선발 방법, 그리고 인공 다능성 줄기 세포의 제조 방법
CN106754729B (zh) * 2016-12-31 2020-03-17 内蒙古赛科星家畜种业与繁育生物技术研究院有限公司 利用Xist Tale抑制性转录因子制备诱导性多能干细胞的方法
US11879137B2 (en) 2017-09-22 2024-01-23 The Children's Medical Center Corporation Treatment of type 1 diabetes and autoimmune diseases or disorders
US12247226B2 (en) 2017-10-11 2025-03-11 Fate Therapeutics, Inc. Cellular reprogramming using temporal and transient plasmid vector expression system
BR112020011017A2 (pt) 2017-12-22 2020-11-17 Fate Therapeutics, Inc. células efetoras imunes intensificadas e uso das mesmas
WO2019133714A1 (en) * 2017-12-28 2019-07-04 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Generation of induced pluripotent cells by crispr activation
EP3768827A1 (en) * 2018-03-22 2021-01-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for reprogramming somatic cells
CA3121128A1 (en) 2018-12-02 2020-06-11 Fate Therapeutics, Inc. Immunotherapies using enhanced ipsc derived effector cells
CN109679918A (zh) * 2018-12-25 2019-04-26 合肥中科干细胞再生医学有限公司 一种便捷的人诱导性多能干细胞的制备方法
WO2020203712A1 (ja) * 2019-03-29 2020-10-08 富士フイルム株式会社 特定細胞に分化する能力を有する多能性幹細胞の製造方法およびその応用
CN110564673A (zh) * 2019-09-26 2019-12-13 广东工业大学 一种干细胞培养液及其应用
CA3150477A1 (en) * 2019-12-11 2021-06-17 Luis Haupt MULTIPLICATION OF STEM CELLS CULTURED IN SUSPENSION IN A BIOREACTOR
KR20230040337A (ko) 2020-06-19 2023-03-22 페이트 세러퓨틱스, 인코포레이티드 면역요법 사용을 위한 iPSC-유래 이펙터 세포 유형들의 조합
CN116438295A (zh) * 2020-06-22 2023-07-14 生命技术公司 培养多能细胞悬浮液的方法和组合物
CA3193977A1 (en) * 2020-10-02 2022-04-07 Yi-Shin Lai Improved reprogramming, maintenance and preservation for induced pluripotent stem cells
US20230302044A1 (en) * 2022-03-28 2023-09-28 Steve Reilly Composition to increase cellularlongevity
US20250228943A1 (en) 2022-04-08 2025-07-17 Fate Therapeutics, Inc. Cells having solid tumor targeting backbone and use thereof
EP4504799A1 (en) 2022-04-08 2025-02-12 Fate Therapeutics, Inc. Chimeric antigen receptor for tumor targeting
AU2023358188A1 (en) * 2022-10-12 2025-05-29 Beicell Therapeutics Inc. Methods for chemical reprogramming and pluripotent stem cells
WO2025152036A1 (en) * 2024-01-16 2025-07-24 Chiou Guang Yuh System and method for increasing the transduction capability and reprogramming efficiency in targeting cells and tissues
WO2025208002A1 (en) * 2024-03-28 2025-10-02 Altos Labs, Inc. Targeted expression of regeneration factors in aged/senescent cells
CN118979011A (zh) * 2024-10-22 2024-11-19 杭州瑞普晨创科技有限公司 人多能干细胞单细胞的建系方法

Family Cites Families (153)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US5506337A (en) 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US5010175A (en) 1988-05-02 1991-04-23 The Regents Of The University Of California General method for producing and selecting peptides with specific properties
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
IE66205B1 (en) 1990-06-14 1995-12-13 Paul A Bartlett Polypeptide analogs
US5650489A (en) 1990-07-02 1997-07-22 The Arizona Board Of Regents Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof
US5384253A (en) 1990-12-28 1995-01-24 Dekalb Genetics Corporation Genetic transformation of maize cells by electroporation of cells pretreated with pectin degrading enzymes
AU2515992A (en) 1991-08-20 1993-03-16 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
EP0641781B1 (en) 1991-09-06 2000-07-26 Yoshitomi Pharmaceutical Industries, Ltd. 4-amino(alkyl)cyclohexane-1-carboxamide compound and use thereof
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
US5702932A (en) 1992-07-20 1997-12-30 University Of Florida Microinjection methods to transform arthropods with exogenous DNA
US5288514A (en) 1992-09-14 1994-02-22 The Regents Of The University Of California Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support
US5824837A (en) 1993-07-22 1998-10-20 Merck & Co., Inc. Expression of human interleukin-1β in a transgenic animal
US5519134A (en) 1994-01-11 1996-05-21 Isis Pharmaceuticals, Inc. Pyrrolidine-containing monomers and oligomers
US5593853A (en) 1994-02-09 1997-01-14 Martek Corporation Generation and screening of synthetic drug libraries
US5539083A (en) 1994-02-23 1996-07-23 Isis Pharmaceuticals, Inc. Peptide nucleic acid combinatorial libraries and improved methods of synthesis
US5656610A (en) 1994-06-21 1997-08-12 University Of Southern California Producing a protein in a mammal by injection of a DNA-sequence into the tongue
US5525735A (en) 1994-06-22 1996-06-11 Affymax Technologies Nv Methods for synthesizing diverse collections of pyrrolidine compounds
US5549974A (en) 1994-06-23 1996-08-27 Affymax Technologies Nv Methods for the solid phase synthesis of thiazolidinones, metathiazanones, and derivatives thereof
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US5843780A (en) 1995-01-20 1998-12-01 Wisconsin Alumni Research Foundation Primate embryonic stem cells
US5977322A (en) 1995-06-14 1999-11-02 The Regents Of The University Of California High affinity human antibodies to tumor antigens
US5569588A (en) 1995-08-09 1996-10-29 The Regents Of The University Of California Methods for drug screening
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US5780448A (en) 1995-11-07 1998-07-14 Ottawa Civic Hospital Loeb Research DNA-based vaccination of fish
GB9807935D0 (en) 1998-04-14 1998-06-10 Univ Edinburgh Lineage specific cells and progenitor cells
US5945100A (en) 1996-07-31 1999-08-31 Fbp Corporation Tumor delivery vehicles
NZ334613A (en) 1996-08-12 2002-02-01 Welfide Corp Pharmaceutical agents comprising Rho kinase inhibitor
US5981274A (en) 1996-09-18 1999-11-09 Tyrrell; D. Lorne J. Recombinant hepatitis virus vectors
ATE421329T1 (de) 1997-05-07 2009-02-15 Pharma Mar Sa Verwendung von aplidine zur behandlung von kardiovaskulären erkrankungen
US6270994B1 (en) 1997-06-13 2001-08-07 Japanese Foundation For Cancer Research Smad6 and uses thereof
IL132840A (en) 1997-07-01 2004-12-15 Warner Lambert Co Derivatives 4 - bromo or 4 - benzohydroxamic acid iodine amino iodine and pharmaceutical preparations containing them for use as MEK inhibitors
US5994624A (en) 1997-10-20 1999-11-30 Cotton Incorporated In planta method for the production of transgenic plants
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
US20060263382A1 (en) 1998-06-20 2006-11-23 Richard Hotchkiss Membrane-permeant peptide complexes for treatment of sepsis
JP2002521025A (ja) 1998-07-24 2002-07-16 ザ カーネギー インスチチューション オブ ワシントン 増殖因子のＴＧＦ−βファミリーのメンバーを使用する、生殖系列幹細胞の維持および増殖のための方法。
GB9819912D0 (en) 1998-09-11 1998-11-04 Univ Edinburgh Propagation and/or derivation of embryonic stem cells
BR9916785A (pt) 1999-01-07 2001-10-23 Warner Lambert Co Tratamento de asma com inibidores mek
US6703420B1 (en) 1999-03-19 2004-03-09 Bristol-Myers Squibb Pharma Company Amino-thio-acrylonitriles as MEK inhibitors
WO2000078351A1 (en) 1999-06-18 2000-12-28 Mitsubishi Pharma Corporation Osteogenesis promoters
US6730293B1 (en) 1999-08-24 2004-05-04 Cellgate, Inc. Compositions and methods for treating inflammatory diseases of the skin
AU6865100A (en) 1999-09-02 2001-04-10 Mitsubishi Pharma Corporation Osteogenesis promoting agents
US20020142457A1 (en) 1999-12-28 2002-10-03 Akihiro Umezawa Cell having the potentiality of differentiation into cardiomyocytes
US6692736B2 (en) 2000-03-24 2004-02-17 Cell Genesys, Inc. Cell-specific adenovirus vectors comprising an internal ribosome entry site
JP3811775B2 (ja) 2000-07-19 2006-08-23 ワーナー−ランバート カンパニー リミティド ライアビリティー カンパニー ４−ヨードフェニルアミノベンズヒドロキサム酸の酸素化エステル
US20030087919A1 (en) 2001-03-23 2003-05-08 Bayer Corporation Rho-kinase inhibitors
US20030125344A1 (en) 2001-03-23 2003-07-03 Bayer Corporation Rho-kinase inhibitors
DE60234824D1 (de) 2001-05-01 2010-02-04 Ca Nat Research Council Induzierbares expressionssystem in eukaryotischen zellen
JPWO2003027277A1 (ja) 2001-09-21 2005-01-06 独立行政法人 科学技術振興機構 再プログラム化因子のスクリーニング方法、該方法によりスクリーニングされた再プログラム化因子および該再プログラム化因子を利用する方法、並びに、未分化融合細胞を分化させる方法および細胞、組織、臓器の製造方法
PT1456380E (pt) 2001-11-02 2012-07-23 Giuliani Int Ltd Inibidores smad7 para o tratamento de doenças do snc
JP4505228B2 (ja) 2002-01-10 2010-07-21 バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト Ｒｈｏ−キナーゼ阻害剤
JP4423043B2 (ja) 2002-01-23 2010-03-03 バイエル ファーマセチカル コーポレーション Ｒｈｏ−キナーゼ阻害剤
EP1470121B1 (en) 2002-01-23 2012-07-11 Bayer HealthCare LLC Pyrimidine derivatives as rho-kinase inhibitors
AU2003210405A1 (en) 2002-03-05 2003-09-16 Artemis Pharmaceuticals Gmbh Inbred embryonic stem-cell derived mice
UA77765C2 (en) 2002-03-13 2007-01-15 Array Biopharma Inc N3 alkylated derivatives of benzimidazole as mek inhibitors
EP1500643A4 (en) 2002-04-03 2007-03-28 Dainippon Sumitomo Pharma Co BENZAMIDE DERIVATIVES
GB0210539D0 (en) 2002-05-08 2002-06-19 Univ Edinburgh Control of es cell self renewal and lineage specification, and medium therefor
DE50304983D1 (de) 2002-10-28 2006-10-19 Bayer Healthcare Ag Heteroaryloxy-substituierte phenylaminopyrimidine als rho-kinaseinhibitoren
EP1562601A1 (en) 2002-11-15 2005-08-17 Warner-Lambert Company LLC Combination chemotherapy comprising a mek inhibitor and capecitabine for treating cancer
MXPA05008309A (es) 2003-02-10 2005-09-20 Amgen Inc Ligandos de receptor vaniloide y su uso en tratamientos.
AU2003901099A0 (en) 2003-03-11 2003-03-27 Es Cell International Pte Ltd. Methods of inducing differentiation of stem cells
US20050075276A1 (en) 2003-03-14 2005-04-07 Christopher Rudd Use of inhibitors of glycogen synthase-3 to augment CD28 dependent -T-cell responses
US20070010008A1 (en) 2005-06-29 2007-01-11 Tissuetech, Inc. Ex vivo expansion of primary animal cells
AU2004316996A1 (en) 2003-06-20 2005-09-15 The Regents Of The University Of California Polypeptide transduction and fusogenic peptides
BRPI0414961A (pt) 2003-10-03 2006-11-07 Keiichi Fukuda processo de indução da diferenciação de células tronco em células do miocárdio
CN1863779B (zh) 2003-10-15 2010-05-05 宇部兴产株式会社 吲唑衍生物
KR20070030164A (ko) 2003-10-16 2007-03-15 더 유니버시티 코트, 더 유니버시티 오브 에딘버러 Ｅｓ 세포 자가 재생 및 계통 지정의 조절, 및 이를 위한배지
WO2005049812A1 (en) 2003-11-19 2005-06-02 Australian Stem Cell Centre Limited Methods for producing blood products from pluripotent cells in cell culture
HRP20110105T4 (hr) 2003-11-19 2013-03-31 Array Biopharma, Inc. Mek heterocikliäśki inhibitori
US20070269412A1 (en) 2003-12-02 2007-11-22 Celavie Biosciences, Llc Pluripotent cells
US20080275062A1 (en) 2004-01-30 2008-11-06 David Harold Drewry Chemical Compounds
CN1997660A (zh) 2004-04-21 2007-07-11 芝加哥大学 肌球蛋白轻链激酶抑制剂及其使用
CA2576872C (en) 2004-08-13 2013-11-12 University Of Georgia Research Foundation, Inc. Compositions and methods for self-renewal and differentiation in human embryonic stem cells
WO2006026473A2 (en) 2004-08-25 2006-03-09 University Of Georgia Research Foundation, Inc. METHODS AND COMPOSITIONS UTILIZING MYC AND GSK3ß TO MANIPULATE THE PLURIPOTENCY OF EMBRYONIC STEM CELLS
WO2006088867A2 (en) 2005-02-15 2006-08-24 Medistem Laboratories, Incorporated Method for expansion of stem cells
BRPI0610139A2 (pt) 2005-05-18 2010-06-01 Array Biopharma Inc inibidores heterocìclicos de mek e métodos de uso dos mesmos
JP4395193B2 (ja) 2005-08-01 2010-01-06 ニューポテンシャル，インコーポレイテッド 回復能を有する再プログラムされた細胞の作製
US20080242594A1 (en) 2005-09-08 2008-10-02 Mckay Ronald D G Methods for Promoting Stem Cell Proliferation and Survival
US8217042B2 (en) 2005-11-11 2012-07-10 Zentaris Gmbh Pyridopyrazines and their use as modulators of kinases
US20090227032A1 (en) 2005-12-13 2009-09-10 Kyoto University Nuclear reprogramming factor and induced pluripotent stem cells
CN101864392B (zh) 2005-12-13 2016-03-23 国立大学法人京都大学 核重新编程因子
GB0601538D0 (en) 2006-01-26 2006-03-08 Univ Birmingham Epigenetic analysis
JPWO2007088651A1 (ja) 2006-02-01 2009-06-25 国立大学法人 東京大学 ＴＧＦ−βシグナル阻害剤と抗腫瘍剤の組み合せ使用
US7541186B2 (en) 2006-02-22 2009-06-02 University Of Washington Method of generating human retinal progenitors from embryonic stem cells
GB0615327D0 (en) 2006-03-30 2006-09-13 Univ Edinburgh Culture medium containing kinase inhibitors and uses thereof
EP1999249B8 (en) 2006-03-30 2012-02-15 The University Court Of The University of Edinburgh Culture medium containing kinase inhibitors. and uses thereof
US8741643B2 (en) 2006-04-28 2014-06-03 Lifescan, Inc. Differentiation of pluripotent stem cells to definitive endoderm lineage
SE534150C2 (sv) 2006-05-02 2011-05-10 Wisconsin Alumni Res Found Förfarande för differentiering av stamceller till celler av den endodermala och pankreatiska utvecklingslinjen
WO2008005268A1 (en) 2006-06-30 2008-01-10 Schering Corporation Substituted piperidines that increase p53 activity and the uses thereof
AR061974A1 (es) 2006-07-14 2008-08-10 Novartis Ag Derivados de pirimidina como inhibidores de alk, composiciones farmaceuticas y procesos de obtencion
US20080020014A1 (en) 2006-07-19 2008-01-24 Paul Consigny Implantable devices containing nuclear receptor ligands for the treatment of vascular and related disorders
ZA200901914B (en) 2006-09-22 2010-06-30 Riken Stem cell culture medium and method
JP2008099662A (ja) 2006-09-22 2008-05-01 Institute Of Physical & Chemical Research 幹細胞の培養方法
GB0622395D0 (en) 2006-11-09 2006-12-20 Univ Cambridge Tech Methods relating to pluripotent cells
CA2675445C (en) 2007-01-17 2014-11-04 Wisconsin Alumni Research Foundation Improved culture of stem cells
WO2008088882A2 (en) 2007-01-19 2008-07-24 The J. David Gladstone Institutes Methods of generating cardiomyocytes
CN101641436A (zh) 2007-01-30 2010-02-03 佐治亚大学研究基金会 用于产生内胚层和中胚层细胞系及多能游走细胞（mmc）的早期中胚层细胞即稳定的中内胚层细胞群
US8158415B2 (en) 2007-02-27 2012-04-17 Procell Therapeutics Inc. Combined use of cell permeable Nanog and Oct4 for increasing self-renewal and suppressing differentiation of stem cells
ES2703592T3 (es) 2007-03-07 2019-03-11 Mei Pharma Inc Combinación de agente anticancerígeno de bencimidazol y un segundo agente anticancerígeno
WO2008126932A2 (en) 2007-04-09 2008-10-23 Riken Epigenetical regulation of brain plasticity
JP5395058B2 (ja) 2007-04-18 2014-01-22 ハダシット メディカル リサーチ サーヴィシーズ アンド ディヴェロップメント リミテッド 幹細胞に由来する網膜色素上皮細胞
US7878210B2 (en) 2007-06-04 2011-02-01 Philip Morris Usa Inc. Cellulose acetate fiber modification
US8648069B2 (en) 2007-06-08 2014-02-11 Abbvie Inc. 5-substituted indazoles as kinase inhibitors
JP2008307007A (ja) 2007-06-15 2008-12-25 Bayer Schering Pharma Ag 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞
US9213999B2 (en) 2007-06-15 2015-12-15 Kyoto University Providing iPSCs to a customer
DK2173863T3 (en) 2007-06-29 2019-01-21 Fujifilm Cellular Dynamics Inc Automated method and apparatus for embryonic stem cell culture
WO2009032456A2 (en) 2007-08-01 2009-03-12 Primegen Biotech Llc Non-viral delivery of transcription factors that reprogram human somatic cells into a stem cell-like state
WO2009032194A1 (en) 2007-08-31 2009-03-12 Whitehead Institute For Biomedical Research Wnt pathway stimulation in reprogramming somatic cells
AU2008297024B2 (en) 2007-10-31 2014-08-28 Kyoto University Nuclear reprogramming method
WO2009061442A1 (en) 2007-11-06 2009-05-14 Children's Medical Center Corporation Method to produce induced pluripotent stem (ips) cells form non-embryonic human cells
JP4604076B2 (ja) 2007-11-07 2010-12-22 国立大学法人静岡大学 燃料電池用電解質膜
EP2227540A4 (en) 2007-11-29 2011-11-02 Children S Hospital Of Orange County DIFFERENTIATION OF HUMAN CELLS
WO2009067757A1 (en) 2007-11-30 2009-06-04 Cytomatrix Pty Ltd Methods of inducing pluripotency involving oct4 protein
EP2227241A1 (en) 2007-11-30 2010-09-15 Cytomatrix PTY LTD Methods of inducing pluripotency involving sox2 protein
US20110061118A1 (en) 2008-03-17 2011-03-10 Helmholtz Zentrum Munchen Vectors and methods for generating vector-free induced pluripotent stem (ips) cells using site-specific recombination
CA2718904C (en) 2008-03-17 2017-01-03 The Scripps Research Institute Combined chemical and genetic approaches for generation of induced pluripotent stem cells
CN101550406B (zh) 2008-04-03 2016-02-10 北京大学 制备多潜能干细胞的方法,试剂盒及用途
KR101685209B1 (ko) * 2008-07-30 2016-12-09 고쿠리츠 다이가쿠 호진 교토 다이가쿠 유도된 다능성 줄기 세포의 효율적인 확립 방법
US8298825B1 (en) 2008-08-25 2012-10-30 The General Hospital Corporation TGF-beta receptor inhibitors to enhance direct reprogramming
IL320421A (en) 2008-11-04 2025-06-01 Viacyte Inc Stem cell aggregate suspension compositions and methods for differentiation thereof
ES2898303T3 (es) 2008-12-03 2022-03-07 Scripps Research Inst Cultivos de células madre
ES2645869T3 (es) 2008-12-17 2017-12-11 The Scripps Research Institute Generación y mantenimiento de células madre
US20100150889A1 (en) * 2008-12-17 2010-06-17 The Uab Research Foundation Polycistronic Vector For Human Induced Pluripotent Stem Cell Production
US20120122212A1 (en) 2009-03-06 2012-05-17 Marica Grskovic Tgf-beta pathway inhibitors for enhancement of cellular reprogramming of human cells
EP2414510A4 (en) * 2009-04-03 2013-04-17 Mclean Hospital Corp INDUCED PLURIPOTENTIAL STEM CELLS
US8609417B2 (en) 2009-04-13 2013-12-17 The Regents Of The University Of California Methods and compositions for stem cell cultures
EP2435558A4 (en) 2009-05-27 2013-05-22 Salk Inst For Biological Studi GENETICALLY CORRECTED NON-DISABLED INDUCED PLURIPOTENTER STEM CELLS
US8524498B2 (en) 2009-05-29 2013-09-03 The General Hospital Corporation Methods and compositions for homologous recombination in human cells
JP5777113B2 (ja) 2009-05-29 2015-09-09 学校法人慶應義塾 人工多能性幹細胞のクローンの選択方法
DK2548950T3 (en) 2009-06-05 2017-12-11 Cellular Dynamics Int Inc Reprogramming of T cells and hematopoietic cells
KR101774206B1 (ko) 2009-08-07 2017-09-04 고쿠리츠 다이가쿠 호진 교토 다이가쿠 유도된 다능성 줄기 세포의 효율적인 확립 방법
JP5808331B2 (ja) 2009-10-16 2015-11-10 ザ スクリプス リサーチ インスティテュート 多能性細胞の誘導法
MX353245B (es) 2009-10-31 2018-01-08 New World Laboratories Inc Star Metodos para reprogramar células y sus usos.
JP5898086B2 (ja) 2009-11-04 2016-04-06 セルラー ダイナミクス インターナショナル， インコーポレイテッド 化学物質を用いるエピソームリプログラミング
EP3633025B1 (en) * 2009-11-12 2022-09-14 Technion Research & Development Foundation Ltd. Culture media, cell cultures and methods of culturing pluripotent stem cells in an undifferentiated state
JP5827220B2 (ja) * 2010-01-22 2015-12-02 国立大学法人京都大学 人工多能性幹細胞の樹立効率改善方法
WO2011103343A2 (en) 2010-02-17 2011-08-25 Biotime Inc. Methods for telomere length and genomic dna quality control analysis in pluripotent stem cells
US8486701B2 (en) 2010-03-05 2013-07-16 University Of Houston ETS2 and MESP1 generate cardiac progenitors from fibroblasts
ES2624780T3 (es) 2010-03-31 2017-07-17 The Scripps Research Institute Reprogramación de células
US20110306516A1 (en) 2010-06-15 2011-12-15 The New York Stem Cell Foundation Methods for producing induced pluripotent stem cells
EP2582794B2 (en) 2010-06-15 2024-04-24 FUJIFILM Cellular Dynamics, Inc. Generation of induced pluripotent stem cells from small volumes of peripheral blood
WO2011158852A1 (ja) 2010-06-15 2011-12-22 国立大学法人東京大学 誘導型多能性幹細胞の製造方法
US8765470B2 (en) 2010-08-04 2014-07-01 Cellular Dynamics International, Inc. Reprogramming immortalized B-cells to induced pluripotent stem cells
KR101975688B1 (ko) 2010-12-22 2019-05-07 페이트 세러퓨틱스, 인코포레이티드 단세포 분류 및 iPSC의 증강된 재프로그래밍을 위한 세포 배양 플랫폼
WO2013070852A2 (en) 2011-11-08 2013-05-16 Emory University Compounds and compositions used to epigenetically transform cells and methods related thereto
HK1203081A1 (en) 2011-12-08 2015-10-16 Fred Hutchinson Cancer Research Center Compositions and methods for enhanced generation of hematopoietic stem/progenitor cells
WO2013159103A1 (en) * 2012-04-20 2013-10-24 Whitehead Institute For Biomedical Research Programming and reprogramming of cells
WO2013176197A1 (ja) 2012-05-22 2013-11-28 国立大学法人 東京大学 抗原特異的ｔ細胞の製造方法
US9166832B1 (en) 2013-10-04 2015-10-20 Altera Corporation Methods and apparatus for decision feedback equalization adaptation
KR102670874B1 (ko) 2014-03-04 2024-05-31 페이트 세러퓨틱스, 인코포레이티드 개선된 재프로그래밍 방법 및 세포 배양 플랫폼
EP3362570A4 (en) 2015-10-16 2019-03-20 Fate Therapeutics, Inc. PLATFORM FOR THE INDUCTION AND MAINTENANCE OF BASIC STATUS PLURIPOTENCE
EP3371314B1 (en) 2015-11-04 2023-07-05 Fate Therapeutics, Inc. Genomic engineering of pluripotent cells

Also Published As

Publication number Publication date
EP4647498A2 (en) 2025-11-12
CN120536340A (zh) 2025-08-26
AU2024205273A1 (en) 2024-08-22
JP2023126627A (ja) 2023-09-07
AU2015227184A1 (en) 2016-09-15
KR20160130260A (ko) 2016-11-10
KR102670874B1 (ko) 2024-05-31
US20220228125A1 (en) 2022-07-21
AU2015227184B2 (en) 2021-05-20
JP2021000107A (ja) 2021-01-07
JP7738035B2 (ja) 2025-09-11
KR20220147728A (ko) 2022-11-03
CN120536341A (zh) 2025-08-26
SG11201606934SA (en) 2016-09-29
AU2021218109A1 (en) 2021-09-09
EP3114214B1 (en) 2023-11-01
JP6722108B2 (ja) 2020-07-15
EP3805369A1 (en) 2021-04-14
PT3114214T (pt) 2024-01-03
KR102340553B1 (ko) 2021-12-21
AU2021218109B2 (en) 2024-05-02
ES2966757T3 (es) 2024-04-24
US20170073643A1 (en) 2017-03-16
JP2022082668A (ja) 2022-06-02
KR102460549B1 (ko) 2022-10-28
WO2015134652A1 (en) 2015-09-11
KR20240091064A (ko) 2024-06-21
JP2019187454A (ja) 2019-10-31
EP3114214A4 (en) 2017-08-09
JP2025114793A (ja) 2025-08-05
EP3805369B1 (en) 2025-09-03
CA2941004A1 (en) 2015-09-11
JP2018086018A (ja) 2018-06-07
EP3805369C0 (en) 2025-09-03
EP3114214A1 (en) 2017-01-11
CN106414721A (zh) 2017-02-15
JP7170600B2 (ja) 2022-11-14
KR20210111884A (ko) 2021-09-13
JP7516452B2 (ja) 2024-07-16
US11268069B2 (en) 2022-03-08
JP2017506904A (ja) 2017-03-16
EP3604499A1 (en) 2020-02-05
SG10201807292YA (en) 2018-09-27

Similar Documents

Publication Publication Date Title
ES3050608T3 (en) Improved reprogramming methods and cell culture platforms
LU92752B1 (en) Cell culture apparatus and culture methods using same
GB201611982D0 (en) Cell culture
SG11201703493SA (en) Cell culture insert
EP3124589A4 (en) Cell culture method and cell culture system
SG11201705853VA (en) Cell culture device and cell culture method
SG11201609916RA (en) Culture method and cell mass
EP3115450A4 (en) Cell culture method and cell culture device
SG11201706090SA (en) Cell culturing method and kit
LT3365107T (lt) Ląstelių kultūra
EP3196292A4 (en) Cell culture apparatus and method
PL3865563T3 (pl) Materiały i sposoby do przedłużania pożywki do hodowli komórkowej
EP3107996A4 (en) Tscm cells and methods for use
SG11202004935UA (en) Cell culture methods
PL3132020T3 (pl) Naczynie do hodowli komórek i jego zastosowanie
EP3235902A4 (en) Cell culture method and cell culture device
SG11201702475VA (en) Methods and compositions for modulating th-gm cell function
EP3192295A4 (en) Method and arrangement for cell combination
PL3287521T3 (pl) Hodowla komórkowa
SG11201702897WA (en) Cell culture bag and cell culture method
PL3630946T3 (pl) Sposoby hodowli komórkowych
GB201418980D0 (en) Cell assay kit and method
TWI563082B (en) Cell culture device
GB201421342D0 (en) Cell culture
SG10202010002RA (en) Cell culture